Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden

Table 3 Cost effectiveness of clinical scenario analyses

Scenario	Model outcomes	Norway			Sweden
Scenario	Model outcomes	SZC	Usual care	Difference	SZC	Usual care	Difference
Serum K⁺ treatment threshold ≥ 5.1 mmol/L	Total costs	79,951	73,864	6,087	61,988	57,210	4,777
	Total LYs	4.925	4.728	0.197	5.056	4.849	0.206
	Total QALYs	3.041	2.916	0.125	3.053	2.925	0.128
	Cost/LY	30,958			23,168
	Cost/QALY (ICER)	48,862			37,253
Patients initiate with CKD stage 3a	Total costs	104,546	101,983	2,563	82,625	78,926	3,699
	Total LYs	7.207	6.821	0.385	7.500	7.085	0.415
	Total QALYs	4.629	4.384	0.245	4.720	4.461	0.259
	Cost/LY	6,650			8,910
	Cost/QALY (ICER)	10,457			14,259
Patients initiate with CKD stage 4	Total costs	57,045	55,733	1,312	42,823	41,634	1,190
	Total LYs	2.690	2.496	0.195	2.720	2.521	0.199
	Total QALYs	1.493	1.383	0.110	1.469	1.359	0.110
	Cost/LY	6,744			5,979
	Cost/QALY (ICER)	11,908			10,798
Patients permitted to progress to RRT	Total costs	138,549	128,573	9,976	114,940	105,370	9,570
	Total LYs	7.195	6.558	0.636	7.649	6.954	0.694
	Total QALYs	4.152	3.798	0.354	4.322	3.942	0.380
	Cost/LY	15,679			13,783
	Cost/QALY (ICER)	28,211			25,179

All costs presented in Euros. Disaggregated results can be found in the data supplement, Tables S9–S11
CKD Chronic kidney disease, ICER Incremental cost-effectiveness ratio, LY Life year, QALY Quality-adjusted life year, RRT Renal replacement therapy, SZC sodium zirconium cyclosilicate

ISSN: 1471-2369